NewsBenzingaArrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies Benzinga 2026.10.14 11:32 (GMT+0) Open on Benzinga Other news Nscale's IPO plans hit another snag: Microsoft exits data center project Inflation Shakes Fed Outlook Crude Oil Surges, Sanders Targets Oil Companies and More: This Week in Economy AMC CEO Slams Robinhood Again: Stock Tokens Could Affect Company's Capital Structure Hyperscale Data completes tokenization of 5,000 troy ounces of silver; AI subsidiary askROI plans listing in Q2 or Q3 2027 Specter retweet warns community that InfoFi project BILL is a suspected scam, token price has plunged 97% from its high First Financial: Acquisitions Drive 2027 Growth (NASDAQ:THFF)
Inflation Shakes Fed Outlook Crude Oil Surges, Sanders Targets Oil Companies and More: This Week in Economy
Hyperscale Data completes tokenization of 5,000 troy ounces of silver; AI subsidiary askROI plans listing in Q2 or Q3 2027
Specter retweet warns community that InfoFi project BILL is a suspected scam, token price has plunged 97% from its high
